Electrochemotherapy as first line cancer treatment: Experiences from veterinary medicine in developing novel protocols

E. P. Spugnini, T. Azzarito, S. Fais, M. Fanciulli, A. Baldi

Research output: Contribution to journalArticle

Abstract

Tumor microenvironment is one of the major obstacles to the efficacy of chemotherapy in cancer patients. The abnormal blood flow within the tumor results in uneven drug distribution. Electrochemotherapy (ECT) is a tumor treatment that adopts the systemic or local delivery of anticancer drugs with the application of permeabilizing electric pulses having appropriate amplitude and waveforms. This allows the use of lipophobic drugs that frequently have a narrow therapeutic index maintaining at the same time a reduced patient morbidity and preserving appropriate anticancer efficacy. Its use in humans is addressed to the treatment of cutaneous neoplasms or the palliation of skin tumor metastases, and a standard operating procedure has been devised. On the other hand, in veterinary oncology this approach is gaining popularity, thus becoming a first line treatment for different cancer histotypes, in a variety of clinical conditions due to its high efficacy and low toxicity. This review summarizes the state of the art in veterinary oncology as a preclinical model and reports the new protocols in terms of drugs and therapy combination that have been developed.

Original languageEnglish
Pages (from-to)43-52
Number of pages10
JournalCurrent Cancer Drug Targets
Volume16
Issue number1
Publication statusPublished - Jan 1 2016

Fingerprint

Electrochemotherapy
Veterinary Medicine
Neoplasms
Pharmaceutical Preparations
Therapeutics
Tumor Microenvironment
Skin Neoplasms
Combination Drug Therapy
Neoplasm Metastasis
Morbidity
Drug Therapy
Skin

Keywords

  • Adjuvant
  • Bleomycin
  • Cisplatin
  • Electroporation
  • Neoadjuvant
  • Pets
  • Therapeutic index

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Electrochemotherapy as first line cancer treatment : Experiences from veterinary medicine in developing novel protocols. / Spugnini, E. P.; Azzarito, T.; Fais, S.; Fanciulli, M.; Baldi, A.

In: Current Cancer Drug Targets, Vol. 16, No. 1, 01.01.2016, p. 43-52.

Research output: Contribution to journalArticle

@article{be45ad3d6f784ad4a656645700444f33,
title = "Electrochemotherapy as first line cancer treatment: Experiences from veterinary medicine in developing novel protocols",
abstract = "Tumor microenvironment is one of the major obstacles to the efficacy of chemotherapy in cancer patients. The abnormal blood flow within the tumor results in uneven drug distribution. Electrochemotherapy (ECT) is a tumor treatment that adopts the systemic or local delivery of anticancer drugs with the application of permeabilizing electric pulses having appropriate amplitude and waveforms. This allows the use of lipophobic drugs that frequently have a narrow therapeutic index maintaining at the same time a reduced patient morbidity and preserving appropriate anticancer efficacy. Its use in humans is addressed to the treatment of cutaneous neoplasms or the palliation of skin tumor metastases, and a standard operating procedure has been devised. On the other hand, in veterinary oncology this approach is gaining popularity, thus becoming a first line treatment for different cancer histotypes, in a variety of clinical conditions due to its high efficacy and low toxicity. This review summarizes the state of the art in veterinary oncology as a preclinical model and reports the new protocols in terms of drugs and therapy combination that have been developed.",
keywords = "Adjuvant, Bleomycin, Cisplatin, Electroporation, Neoadjuvant, Pets, Therapeutic index",
author = "Spugnini, {E. P.} and T. Azzarito and S. Fais and M. Fanciulli and A. Baldi",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "16",
pages = "43--52",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Electrochemotherapy as first line cancer treatment

T2 - Experiences from veterinary medicine in developing novel protocols

AU - Spugnini, E. P.

AU - Azzarito, T.

AU - Fais, S.

AU - Fanciulli, M.

AU - Baldi, A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Tumor microenvironment is one of the major obstacles to the efficacy of chemotherapy in cancer patients. The abnormal blood flow within the tumor results in uneven drug distribution. Electrochemotherapy (ECT) is a tumor treatment that adopts the systemic or local delivery of anticancer drugs with the application of permeabilizing electric pulses having appropriate amplitude and waveforms. This allows the use of lipophobic drugs that frequently have a narrow therapeutic index maintaining at the same time a reduced patient morbidity and preserving appropriate anticancer efficacy. Its use in humans is addressed to the treatment of cutaneous neoplasms or the palliation of skin tumor metastases, and a standard operating procedure has been devised. On the other hand, in veterinary oncology this approach is gaining popularity, thus becoming a first line treatment for different cancer histotypes, in a variety of clinical conditions due to its high efficacy and low toxicity. This review summarizes the state of the art in veterinary oncology as a preclinical model and reports the new protocols in terms of drugs and therapy combination that have been developed.

AB - Tumor microenvironment is one of the major obstacles to the efficacy of chemotherapy in cancer patients. The abnormal blood flow within the tumor results in uneven drug distribution. Electrochemotherapy (ECT) is a tumor treatment that adopts the systemic or local delivery of anticancer drugs with the application of permeabilizing electric pulses having appropriate amplitude and waveforms. This allows the use of lipophobic drugs that frequently have a narrow therapeutic index maintaining at the same time a reduced patient morbidity and preserving appropriate anticancer efficacy. Its use in humans is addressed to the treatment of cutaneous neoplasms or the palliation of skin tumor metastases, and a standard operating procedure has been devised. On the other hand, in veterinary oncology this approach is gaining popularity, thus becoming a first line treatment for different cancer histotypes, in a variety of clinical conditions due to its high efficacy and low toxicity. This review summarizes the state of the art in veterinary oncology as a preclinical model and reports the new protocols in terms of drugs and therapy combination that have been developed.

KW - Adjuvant

KW - Bleomycin

KW - Cisplatin

KW - Electroporation

KW - Neoadjuvant

KW - Pets

KW - Therapeutic index

UR - http://www.scopus.com/inward/record.url?scp=84953743713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953743713&partnerID=8YFLogxK

M3 - Article

C2 - 26712353

AN - SCOPUS:84953743713

VL - 16

SP - 43

EP - 52

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 1

ER -